Updated hourlyHourly refreshMon, Oct 26, 2026
Press Release Database
Recent press releases, indexed by topic.
Finance · Healthcare
NAARDEN, The Netherlands and MIAMI, Aug. 26, 2026 -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or well-tolerated, today announced that it will present data from its obicetrapib development program at the European Society of Cardiology (ESC) Congress 2026, taking place August 28 – 31, 2026 in Munich, Germany.
Aug 26 · 12:00·GlobeNewswire
Finance · Biotech & pharma
RADNOR, Pa., Aug. 26, 2026 -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and aldosterone-related adverse outcomes in comorbid conditions such as chronic kidney disease, obstructive sleep apnea and other diseases driven by dysregulated aldosterone, announced today that management will be participating in the Wells Fargo 21st Annual Healthcare Conference being held in Boston on September 8-10, 2026.
Aug 26 · 12:00·GlobeNewswire
Finance · Healthcare
HOUSTON, Aug. 26, 2026 -- Tvardi Therapeutics, Inc. (“Tvardi”) (NASDAQ: TVRD), a clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting STAT3 to treat inflammatory and proliferative diseases, today announced that management will participate in the following upcoming investor events:
Aug 26 · 12:00·GlobeNewswire
Healthcare · Biotech & pharma
U.S. FDA Orphan Drug Designation underscores darizmetinib’s potential to address a significant unmet need following liver resection
Aug 26 · 09:00·GlobeNewswire
Biotech & pharma
Opportunities include single-use, automated, sensor-rich bioreactors for high-throughput biologics development; compact perfusion systems; Asia-Pacific and CDMO expansion; and solutions improving scale-up fidelity, material safety and process reproducibility.
Opportunities include single-use, automated, sensor-rich bioreactors for high-throughput biologics development; compact perfusion systems; Asia-Pacific and CDMO expansion; and solutions improving scale-up fidelity, material safety and process reproducibility.
Aug 26 · 08:05·GlobeNewswire
Healthcare · Industrial
Expanding clinical pipelines and outsourcing are boosting CDMO demand. Opportunities include scalable cell/vector production, non-viral platforms, automation and faster analytics.
Expanding clinical pipelines and outsourcing are boosting CDMO demand. Opportunities include scalable cell/vector production, non-viral platforms, automation and faster analytics.
Aug 26 · 08:04·GlobeNewswire
Healthcare · Biotech & pharma
LONDON, August 26, 2026--VirTus Respiratory Research Ltd, a specialist respiratory contract research organisation (CRO), founded by Imperial College London investigators Professor Sebastian Johnston and Dr Michael Edwards, today highlighted its role in the preclinical development of Apollo Therapeutics’ and Imperial’s APL-10456, following the announcement of positive initial data from the vaccine’s Phase 1 clinical trial.
Aug 26 · 08:00·Business Wire
Finance · SaaS
Tokyo, Japan and Cambridge, UK, 26 August 2026 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) announces that its partner Neurocrine Biosciences Inc. (“Neurocrine”) has received IND Acceptance from the U.S. Food and Drug Administration (FDA) for a Phase 2 study of NBI-1117567 (“NBI-’567”) for Alzheimer's cognition. Nxera will receive an IND Acceptance milestone payment of US$10 million from Neurocrine pursuant to the agreement. The milestone payment is expected to be recognised in full as revenue in Q3 FY2026. NBI-’567 is an investigational, orally administered, muscarinic M1 receptor preferring agonist discovered using Nxera’s proprietary NxWave™ drug discovery platform.
Aug 26 · 07:33·GlobeNewswire
Healthcare · Industrial
Commercial collaboration combines 4basebio's synthetic DNA technology with Genezen's viral vector development and manufacturing expertise to support gene therapy programs from early development through clinical and commercial manufacturing. CAMBRIDGE, United Kingdom and INDIANAPOLIS, Aug....
Aug 26 · 06:15·PR Newswire
Biotech & pharma
Capricor Therapeutics (CAPR) Investors Have Opportunity to Lead Capricor Therapeutics, Inc. Securities Fraud Lawsuit
Aug 26 · 02:05·GlobeNewswire
Finance · Biotech & pharma
New York, New York--(August 25, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of Aardvark Therapeutics, Inc. (NASDAQ: AARD): (i) common stock pursuant and/or traceable to the registration statement and prospectus (collectively, the "Registration Statement") issued in connection with Aardvark's February 13, 2025 initial public offering ("IPO"); and/or (ii) securities between February 13, 2025 and May 14, 2026, both dates inclusive (the "Class...
Aug 26 · 00:19·Newsfile
Finance · Biotech & pharma
NEW YORK, Aug. 25, 2026 --
WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of ARS Pharmaceuticals, Inc. (NASDAQ: SPRY) between March 9, 2026 and June 24, 2026, inclusive (the “Class Period”), of the important October 5, 2026 lead plaintiff deadline.
Aug 25 · 23:40·GlobeNewswire